New drug duo tested in fight against Tough-to-Treat uterine cancer
NCT ID NCT05761951
Summary
This study is testing whether combining an experimental drug (DKN-01) with an approved immunotherapy (pembrolizumab) can help control advanced or recurrent endometrial cancer. It will involve about 8 women with specific types of this cancer to see if the treatment is effective and safe. The main goal is to see if the combination shrinks tumors and for how long.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.